At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,305 enrolled
Drug / intervention
Multi-cancer early detection testdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Performance of a Pan-cancer Early Detection Model Based on Liquid Biopsy of Various-omics Biomarkers: a Proof of Concept Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences·observational·Posted Jul 22, 2021·Updated Dec 27, 2024
In Brief
An observational study evaluating Multi-cancer early detection test for Cancer. Completed, enrolled 2,305 participants across 1 site.
Detailed Summary
PROMISE is a multi-center, prospective and proof of concept study aimed to evaluate the performance of 3 prototype assays of cell-free DNA (cfDNA) mutation, cfDNA methylation and microRNA (miRNA) expression in early detection of multi-cancer. Assay(s) will be selected for further development. The study will enroll approximately 2035 participants, including participants with cancers and healthy participants.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesChina
CollaboratorsGuangzhou Burning Rock Dx Co., Ltd.
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartJun 2021
First PostedJul 2021
Primary CompletionMar 2022
Study CompletionJun 2022
TodayJul 2026
First PostedJul 22, 2021
Enrollment StartJun 1, 2021
Primary CompletionMar 31, 2022
Study CompletionJun 30, 2022
TodayJul 1, 2026
Enrollment to primary: 10 monthsPosted 4.9 years ago
Interventions
Multi-cancer early detection testdevice
Blood collection and multi-cancer early detection test